Toxicity studies

Dive into injection site reaction assessment

injection site reaction assessment with ex vivo human skin models and cytokine analysis

Immunotoxicity at the injection site

Decoding Injection Site Reactogenicity & Immunotoxicity: A Novel Approach Integrating Human Skin Models with Secretome & Pathway Analytics (SOT 2024)

Emeline Pagès1, Mathias Peries1, Emilie Braun1, Manon Scholaert1, Kimbria Blake3, Alexandra Ochando3 Nicolas Gaudenzio1,2 – 1Genoskin SAS, Toulouse, France – 2Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291 – CNRS UMR5051 – University Toulouse III, France – 3Genoskin Inc, Salem MA, USA

DOWNLOAD POSTER
Genoskin
in vitro human primary mast cells to screen for efficacy and toxicity

Mitigation of injection site reaction (customer poster)

Mitigation of Injection site reactions after subcutaneous administration of Dalcinonacog Alfa (DalcA) in Hemophilia B using preclinical models.

Natacha Le Moan1, Lauren Kelly1, Eric Merle2, Pascal Descargues2, Nicolas Gaudenzio2, Hugo Gagnon3, Anju Chatterji1, Grant E. Blouze1 – 1Catalyst Biosciences, South San Francisco, CA, USA – 2Genoskin, Inc., 4 Technology Way, Salem, MA, 01970, USA – 3Phenoswitch Biosciences, 975 Rue Léon-Trépanier, Sherbrooke, QC J1G 5J6, Canada.

DOWNLOAD POSTER
Genoskin

Local tolerance and injection site reaction

Evaluation of local inflammatory reactions following subcutaneous injection of a pro-inflammatory cocktail in a fully human ex vivo skin model.

C. Jardet (Genoskin), E. Pagès (Genoskin), E. Raude (Genoskin), F. Seeliger (AstraZeneca), L. Brandén (AstraZeneca), E. Braun (Genoskin), M. Ingelsten (LAAS-CNRS), P. Descargues (Genoskin)

DOWNLOAD POSTER

Need more info? Please contact us!

Contact us